[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Views 834
Citations 0
Clinical Trials Update
April 23/30, 2014

Vaccines for Enterovirus 71

JAMA. 2014;311(16):1602. doi:10.1001/jama.2014.3911

Enterovirus 71 (EV71), a major cause of hand, foot, and mouth disease and herpangina in young children, can be controlled by a vaccine, concluded 2 randomized, placebo-controlled phase 3 trials conducted in China. The EV71 genotype C4 has caused thousands of deaths in China and large outbreaks in the Asia-Pacific region.

One trial randomly assigned 12 000 healthy children aged 6 to 71 months to receive 2 injections of inactivated EV71 vaccine or placebo with a 4-week interval between doses (Li R et al. N Engl J Med. 2014;370[9]:829-837). In children who received 2 doses, the vaccine was 97.4% protective against hand, foot, and mouth disease over 11 months and 2 epidemic periods. Most adverse events were mild and were more common in the vaccine group.